MedUnfold

Eli Lilly

Official website ↗

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide (Mounjaro and Zepbound) for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea (56% of 2025 revenues); abemaciclib (Verzenio) for the treatment of advanced or metastatic breast cancers (9% of 2025 revenues); dulaglutide (Trulicity) for the treatment of type 2 diabetes (7% of 2025 revenues); ixekizumab (Taltz) for the treatment of autoimmune diseases (6% of 2025 revenues); and empagliflozin (Jardiance) for the treatment of type 2 diabetes (5% of 2025 revenues). Products that have a minor contribution to revenues include Insulin lispro (Humalog), a modified type of medical insulin; ramucirumab (Cyramza), a fully human monoclonal antibody used for the treatment of cancer; baricitinib (Olumiant), an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia areata, and COVID-19; insulin (Humulin) to treat high blood glucose; and galcanezumab (Emgality), a humanized monoclonal antibody used for the prevention of migraines. In 2024, 67% of the company's revenues came from the United States, 18% came from Europe, 3% came from Japan, and 3% came from China. Lilly was the first company to mass-produce both the polio vaccine, developed in 1955 by Jonas Salk, and insulin. It was one of the first pharmaceutical companies to produce human insulin using recombinant DNA, including Humulin (insulin medication), Humalog (insulin lispro), and the first approved biosimilar insulin product in the US, Basaglar (insulin glargine). It achieved commercial success with major depressive disorder drugs Prozac (fluoxetine) (1986), Cymbalta (duloxetine) (2004), and its antipsychotic medication Zyprexa (olanzapine) (1996), all of which are now off patent and are manufactured by others as generic drugs. In 2005, Lilly brought exenatide to market—the first of the GLP-1 receptor agonists—followed by the GIP and GLP-1 receptor agonist drugs Mounjaro and Zepbound (tirzepatide). The Lilly Endowment, a charitable foundation organized in 1937 by the founding family, owns 9.8% of the company.

Source: https://www.lilly.com/about-lilly

abemaciclibVerzenio
CDK4/6 inhibitor

Verzenio (abemaciclib) is an oral CDK4/6 inhibitor from Eli Lilly. It blocks cyclin-dependent kinases 4 and 6, keeps the retinoblastoma (Rb) protein unphosphorylated, and arrests cancer cells in the G1 phase before they can replicate their DNA. It is used, mostly alongside endocrine therapy, in hormone receptor-positive, HER2-negative breast cancer.

Breast cancer cells grow because molecular "accelerators" called CDK4 and CDK6 keep telling them to divide. Abemaciclib is a kinase inhibitor that swi

baricitinibOlumiant
JAK inhibitor

Olumiant (baricitinib) is an oral Janus kinase inhibitor from Eli Lilly. By damping JAK-STAT signalling it reduces inflammatory cytokine activity, and is used in rheumatoid arthritis after TNF blockers, in hospitalized adults with severe COVID-19, and in severe alopecia areata.

Many inflammatory diseases are driven by cytokines, chemical messages that tell immune cells to stay active. Those messages are relayed inside cells b

cephalexinKeflex
first-generation cephalosporin antibiotic

Keflex (cephalexin) is a first-generation cephalosporin antibiotic that kills bacteria by dismantling their cell walls. It is used for susceptible infections of the respiratory tract, middle ear, skin, bones and urinary tract.

Bacteria need a strong outer wall to keep their shape and survive. Cephalexin belongs to the cephalosporin family of antibiotics and blocks the enzyme

dulaglutideTrulicity
GLP-1 receptor agonist

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist from Eli Lilly for type 2 diabetes. It boosts insulin when glucose is high, calms glucagon and slows stomach emptying, improving blood sugar and reducing major cardiovascular events in at-risk adults.

Dulaglutide mimics a natural hormone, GLP-1, that helps coordinate the body's response to food. It stimulates insulin release when blood sugar rises,

duloxetineCymbalta
serotonin–norepinephrine reuptake inhibitor

Cymbalta (duloxetine) is a serotonin–norepinephrine reuptake inhibitor used for depression, generalized anxiety disorder, diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain. By boosting both serotonin and norepinephrine in the brain and spinal cord, it lifts mood and also turns down the volume on chronic pain signals.

Duloxetine belongs to a group of medicines called serotonin–norepinephrine reuptake inhibitors, or SNRIs. Nerve cells use two chemicals — serotonin an

galcanezumabEmgality
CGRP antagonist

Emgality (galcanezumab) is a monoclonal antibody from Eli Lilly that binds and neutralizes calcitonin gene-related peptide (CGRP), a key signaling molecule in migraine. Given once monthly by injection, it prevents migraine in adults and treats episodic cluster headache.

Galcanezumab is an antibody that targets calcitonin gene-related peptide (CGRP), a small protein released during migraine and cluster headache attacks

insulin lisproHumalog
rapid-acting insulin analogue

Humalog (insulin lispro) is a rapid-acting insulin from Eli Lilly. Two swapped amino acids make it absorb quickly after injection, so it covers the rise in blood sugar that follows a meal, and it is used in type 1 and type 2 diabetes.

Insulin is the hormone that lets cells absorb glucose from the blood. After a meal, blood sugar rises quickly, and the body needs a fast burst of insu

ixekizumabTaltz
IL-17A inhibitor

Taltz (ixekizumab) is an interleukin-17A inhibitor from Eli Lilly that neutralises a key cytokine driving inflammation in skin, joints, and spine. It treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in adults.

Ixekizumab is an injection that blocks a protein called interleukin-17A (IL-17A). IL-17A is a messenger released by overactive immune cells that tells

lebrikizumabEbglyss
IL-13 inhibitor

Ebglyss (lebrikizumab) is a monoclonal antibody from Eli Lilly that selectively neutralises interleukin-13, a key driver of type 2 inflammation in atopic dermatitis. It is used in moderate-to-severe disease in adults and adolescents when topical treatment is not enough.

In atopic dermatitis the immune system overproduces inflammatory signals, and IL-13 is one of the most important. It promotes itching, weakens the ski

tadalafilCialis
PDE5 inhibitor

Cialis (tadalafil) is a PDE5 inhibitor from Eli Lilly. By blocking the enzyme that breaks down cGMP, it enhances blood flow to the penis during sexual stimulation for erectile dysfunction, and it also relaxes smooth muscle in the prostate and bladder to relieve symptoms of benign prostatic hyperplasia.

Tadalafil belongs to a class called PDE5 inhibitors. During sexual stimulation, the body releases chemicals that relax the smooth muscle in the penis

teriparatideForteo
parathyroid hormone analog

Forteo (teriparatide) is a parathyroid hormone analog from Eli Lilly. Given as a daily injection, it stimulates new bone formation and is used to treat osteoporosis in people at high risk of fracture, including postmenopausal women, men with primary osteoporosis, and patients on long-term glucocorticoids.

Teriparatide is a small piece of human parathyroid hormone, the body's own signal for bone remodeling. When given as a once-daily injection, it acts i

tirzepatideMounjaro
dual GIP and GLP-1 receptor agonist

Mounjaro (tirzepatide) is an injectable dual GIP and GLP-1 receptor agonist from Eli Lilly. It improves blood sugar control in type 2 diabetes alongside diet and exercise, and in the European Union it is also approved for weight management in adults with obesity or overweight with a weight-related condition.

Tirzepatide is given by injection and activates the receptors for two natural gut hormones, GIP and GLP-1. Together these signals help the pancreas re